Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.

about

Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.

Item

http://www.wikidata.org/entity/Q50951740

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Insight into the key features ...... olecular dynamics simulations.

@en

Insight into the key features ...... olecular dynamics simulations.

@nl

type

Item

label

Insight into the key features ...... olecular dynamics simulations.

@en

Insight into the key features ...... olecular dynamics simulations.

@nl

prefLabel

Insight into the key features ...... olecular dynamics simulations.

@en

Insight into the key features ...... olecular dynamics simulations.

@nl

P1476

Insight into the key features ...... olecular dynamics simulations.

@en

P2093

Bingren Xiang

http://www.w3.org/2001/XMLSchema#string

Haichun Liu

http://www.w3.org/2001/XMLSchema#string

Haoliang Yuan

http://www.w3.org/2001/XMLSchema#string

Jing Pan

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Libo Yan

http://www.w3.org/2001/XMLSchema#string

Shuai Lu

http://www.w3.org/2001/XMLSchema#string

Tao Lu

http://www.w3.org/2001/XMLSchema#string

Xin Qiao

http://www.w3.org/2001/XMLSchema#string

Yanmin Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of simple potential functions for simulating liquid water

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyraz

Rational Design, Preparation, and Characterization of a Therapeutic Enzyme Mutant with Improved Stability and Function for Cocaine Detoxification

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition

Met, metastasis, motility and more

Invasive growth: a MET-driven genetic programme for cancer and stem cells

P304

1-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07391102.2017.1340852

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28599617

http://www.w3.org/2001/XMLSchema#string

P921

ligand binding